Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at MD Anderson Cancer Center

Sites in Houston, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2395
Shown on this page
12
Current sort
Recently updated
Campus scope
MD Anderson Cancer Center, Houston, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within MD Anderson Cancer Center, Houston, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 193–204 of 2,395 matching trials with a site at MD Anderson Cancer Center, Houston, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02390635
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions
Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI
Procedure · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Active, not recruiting Not applicable Interventional

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

NCT04678427
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
6 Minute Walk Functional Test, Behavioral Intervention, Survey Administration, Timed Get Up and Go Test
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Not yet recruiting Not applicable Interventional

Food Is Medicine In Survivorship (Foodiis-AYA): Examining The Feasibility And Acceptability Of A Remotely-Delivered Meal Kit And Culinary Medicine Program For Survivors Of Adolescent/Young Adult (AYA) Cancer

NCT07871773
Site status not listed — check the official record
View directory record Official record
Conditions
Survivorship, Meal Kit, Culinary Medicine
Interventions
Meal Preps, Questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 25 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Not applicable Interventional

Screening Women With Prior HPV for Anal Neoplasia

NCT05217940
Status at this site: Recruiting
View directory record Official record
Conditions
HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Interventions
Diagnostic tests for anal cancer screening
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
35 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

NCT03059940
Site status not listed — check the official record
View directory record Official record
Conditions
Smoking Cessation
Interventions
Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test
Behavioral · Procedure · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654
Status at this site: Recruiting
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
188
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT06308588
Status at this site: Recruiting
View directory record Official record
Conditions
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

NCT06629584
Status at this site: Recruiting
View directory record Official record
Conditions
Malignant Solid Tumors
Interventions
Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Sotorasib, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
30
States / cities
Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

NCT05056857
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

NCT07604233
Site status not listed — check the official record
View directory record Official record
Conditions
Myeloid Leukemia
Interventions
Fludarabine, Cytarabine, Idarubicin, Filgrastim, Venetoclax, Asciminib, Blinatumomab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:28 PM EDT

About this MD Anderson Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list MD Anderson Cancer Center in Houston, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by M.D. Anderson Cancer Center at any site, browse by condition, or browse by U.S. city.